Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's Disease

Journal of Clinical Pharmacology

Volumn 52, Issue 7, 2012, Pages 1069-1077

  Chen, Cuiping ^a   Cowles, Verne E ^a   Sweeney, Mike ^a   Stolyarov, Igor D ^b   Illarioshkin, Sergey N ^c  

^a Pharmacokinetics Depomed Inc   (United States)

^b RUSSIAN ACADEMY OF SCIENCES   (Russian Federation)

^c RESEARCH CENTER OF NEUROLOGY   (Russian Federation)

Author keywords

extended release; gastric retention; Levodopa carbidopa; Parkinson's disease; pharmacokinetics

Indexed keywords

CARBIDOPA PLUS LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; KNEE PAIN; MALE; MIGRAINE; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VOMITING;

AGED; ANTIPARKINSON AGENTS; AREA UNDER CURVE; CARBIDOPA; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PARKINSON DISEASE; TABLETS; TIME FACTORS;

EID: 84863208358     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011409232     Document Type: Article

References (34)

1. Deleu D, Northway MG, Hannsens Y. Clinical pharmacokinetics and pharmacodynamics properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41:261-309. (Pubitemid 34533757)
2. Chan PL, Nutt JG, Holford NH. Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation. Pharm Res. 2007;24:791-802. (Pubitemid 46411968)
3. Landsberg L, Berardino MB, Silva P. Metabolism of 3H-L-Dopa by the rat gut in vivo-evidence for glucuronide conjugation. Biochem Pharmacol. 1975;24:1167-1174.
4. Tyce GM, Owen CA. Administration of L-3, 4-dihydroxyphenylalanine to rats after complete hepatectomy I: metabolites in tissues. Biochem Pharmacol. 1979;28:3271-3278. (Pubitemid 10198268)
5. Rahman MK, Nagatsu T, Kato T. Aromatic L-amino acid decarboxylase activity in central and peripheral tissues and serum of rats with L-dopa and L-5-hydroxytryptophan as substrates. Biochem Pharmacol. 1981;30:645-649. (Pubitemid 11155195)
6. Bibbiani F, Costantini LC, Patel R, Chase TN. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol. 2005;192:73-78. (Pubitemid 40208539)
7. Blanchet PJ. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-treated monkeys. J Pharmacol Exp Ther. 1995;272:854-859.
8. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson's disease: a clinical and pharmacokinetic study. Arch Neurol. 2005;62:905-910. (Pubitemid 40973452)
9. Jenner P. Molecular mechanism of L-dopa-induced dyskinesia. Neuroscience. 2008;9:665-677.
10. Kurlan RK, Nutt JG, Woodward WR, et al. Duodenal and gastric delivery of levodopa in Parkinsonism. Ann Neurol. 1988;23:589-595.
11. Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease - long-term experience. Acta Neurol Scand. 2001;104:343-348. (Pubitemid 33107378)
12. Nyholm D, Askmark H, Gomes-Trolin, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustainedrelease tablets. Clin Neuropharmacol. 2003;26:156-163. (Pubitemid 36676295)
13. Nyholm D, Aquilonius SM. Levodopa infusion therapy in Parkinson disease: state of the art in 2004. Clin Neuropharmacol. 2004;27:245-256. (Pubitemid 39447222)
14. Hou SYE, Cowles VE, Berner B. Gastric retentive dosage forms: a review. Crit Rev Ther Drug Carrier Syst. 2003;20:459-497.
15. Cowles VE, Gusler G, Chen TF, et al. Gastric emptying and intestinal transit of gastroretentive tablets in the fed state: effect of meal content and tablet size. Gastroenterology. 2004;126:A489-A490.
16. Shojaei AH, Berner B. Gastric retentive dosage forms. In: Li X, Jasti B, eds. Design of Controlled Release Drug Delivery Systems. New York, NY: McGraw Hill; 2005:175-203.
17. Berner B, Cowles V. Case studies in swelling polymeric gastric retentive tablets. Expert Opin Drug Deliv. 2006;3:541-548.
18. GLUMETZA® (metformin hydrochloride) extended release tablet. Available at: http://www.rxlist.com/glumetza-drug.htm. Accessed October 20, 2010.
19. Proquin® XR (ciprofloxacin hydrochloride) extended-release tablets. Available at: http://www.rxlist.com/proquin-xr-drug.htm. Accessed October 20, 2010.
20. Chen C, Cowles V, Hou E. Pharmacokinetics of gabapentin in a novel gastric-retentive extended-release formulation: comparison with an immediate-release formulation and the effect of dose escalation and food [published online ahead of print May 19, 2010]. J Clin Pharmacol.
21. Keats TE, Sistrom C. Gastrointestinal system. In: Atlas of Radiologic Measurement. St. Louis, MO: Mosby; 2001;400-403.
22. Chien YW. Oral drug delivery and delivery systems. In: Novel Drug Delivery Systems, ed J. Swarbrick. New York, NY: Marcel Dekker; 1992:159-163.
23. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker; 1982.
24. Wade DN, Mearrick PT, Morris JL. Active transport of L-dopa in the intestine. Nature. 1973;242:463-465.
25. Rivera-Calimlim L, Dujovne CA, Morgan JP, et al. Absorption and metabolism of L-dopa by the human stomach. Eur J Clin Invest. 1971;1:313-320.
26. Evans MA, Broe GA, Triggs EJ, Cheung M, Creasey H, Paul PD. Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient. Neurology. 1981;31:1288-1294. (Pubitemid 11026847)
27. Hardoff R, Sula M, Tamir A, et al. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord. 2001;16:1041-1047. (Pubitemid 36041216)
28. Nyholm D, Lennernas H. Irregular gastrointestinal drug absorption in Parkinson's disease. Expert Opin Drug Metab Toxicol. 2008;4:193-203. (Pubitemid 351308417)
29. LeWitt PA, Nelson MV, Berchou RC, et al. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. Neurology. 1989;39:45-53. (Pubitemid 20020580)
30. Hardie RJ, Malcolm SL, Lees AJ, Stern GM, Allen JG. The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations. Br J Clin Pharmacol. 1986;22:429-436. (Pubitemid 16003190)
31. Fabbrini G, Juncos J, Mouradian MM, et al. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol. 1987;21:370-376. (Pubitemid 17053274)
32. Kompoliti K, Adler CH, Raman R, et al. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002;58:1418-1422. (Pubitemid 34507176)
33. Martinelli P, Contin M, Scaglione C, Riva R, Albani F, Baruzzi A. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences? J Neurol Sci. 2003;24:192-193. (Pubitemid 37304308)
34. Marooned CD, Parkas JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet. 1977;1:345-349.